A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2 Completed 191 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Timeline

Start: 2015-10-05
Primary completion: 2017-10-25
Completion: 2021-03-10

Publications

Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial. JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	Intravenous
Background	Oxaliplatin	Small molecule	100 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Background	S-1	Small molecule	80 mg	Oral
Background	S-1	Small molecule	120 mg	Oral

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications